Skip to main content
$3.64 -$0.04 (-1.1%)

08:00 PM EDT on 09/24/20

Amarin Corp plc (ADR) (NASDAQ:AMRN)

CAPS Rating: 4 out of 5

The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.

Current Price $3.64 Mkt Cap $1.4B
Open $0.00 P/E Ratio 0.00
Prev. Close $3.64 Div. (Yield) $0.00 (0.0%)
Daily Range $0.00 - $0.00 Volume 2,478,090
52-Wk Range $3.36 - $26.12 Avg. Daily Vol. 9,987,063

Caps

How do you think NASDAQ:AMRN will perform against the market?

Add Stock to CAPS Watchlist

All Players

369 Outperform
30 Underperform
 

All-Star Players

48 Outperform
3 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:AMRN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

bgarzony (72.09)
Submitted September 14, 2018

Potential billion dollar drug if Reduce-it comes out favorably. Vascepa is the only pure EPA product on the market.

chris293 (< 20)
Submitted May 07, 2013

FDA approval for fish oil? What else is going on here, are they selling the good parts of the company for what?

NASDAQ:AMRN VS S&P 500 (SPY)

Fools bullish on NASDAQ:AMRN are also bullish on:

Fools bearish on NASDAQ:AMRN are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about AMRN.

Recs

0
Member Avatar emtking (61.29) Submitted: 11/9/2019 3:06:20 PM : Outperform Start Price: $16.97 NASDAQ:AMRN Score: -83.63

FDA PDUFA date of November 14th, 2019. Essentially, FDA evaluation if concentrated fish oils based pills can reduce incidence of heart disease. In real life, at one point about 7-8 years ago, I owned shares of AMRN when it was under $1/sh. Sold. Lost faith. So sad :(

Recs

0
Member Avatar TL22 (< 20) Submitted: 10/24/2019 3:02:44 AM : Outperform Start Price: $16.34 NASDAQ:AMRN Score: -85.23

The excellent results of the REDUCE-IT study cannot be overlooked. Sales of Vascepa continue to increase as more Doctors become aware of its benefits. FDA - based on the the REDUCE-IT results, a study which the FDA approved the criteria for - will (little to no doubt) allow an expanded label for Vascepa use towards the end of this year. This will result in an immediate increase in share price, which will continue to increase along with the sale of Vascepa.

Recs

0
Member Avatar XMFRendezvous (90.73) Submitted: 3/4/2019 4:19:13 PM : Outperform Start Price: $21.51 NASDAQ:AMRN Score: -98.83

Buy the (buyout) rumor, sell the news.

High upside.. medium-high risk.

Leaderboard

Find the members with the highest scoring picks in AMRN.

Score Leader

vin2066

vin2066 (98.52) Score: +929.25

The Score Leader is the player with the highest score across all their picks in AMRN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
AWWWWW 21.79 12/31/2014 Outperform 1Y $0.95 +283.80% +55.43% +228.37 0 Comment
smoaky < 20 3/28/2007 Underperform 5Y $21.80 -83.33% +141.23% +224.56 0 Comment
bwlink100 < 20 4/13/2007 Underperform 1Y $29.60 -87.72% +136.06% +223.78 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. Lolly131313 95.64 4/19/2007 4/30/2019 Underperform 3Y $37.50 -90.31% +132.57% +222.87 0 Comment
MaxPwr273 70.28 10/26/2011 Underperform 5Y $9.33 -61.04% +160.51% +221.55 0 Comment
zeccoscott < 20 4/20/2007 Underperform 3W $39.20 -90.73% +130.74% +221.47 0 Comment
littlejoyusone < 20 4/20/2007 Underperform 3W $39.20 -90.73% +130.74% +221.47 0 Comment
Playa14 < 20 12/26/2014 12/5/2019 Outperform 5Y $0.99 +267.17% +55.30% +211.87 0 Comment
Luisaespinoza7 < 20 5/18/2012 Underperform 3M $10.34 -64.85% +146.25% +211.10 0 Comment
H8CAGERS < 20 12/1/2011 Underperform 1Y $7.31 -50.27% +159.05% +209.32 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for AMRN.